AMTX-100 is under clinical development by Amytrx Therapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AMTX-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AMTX-100 overview

AMTX-100 is under development for the treatment of mild to moderate atopic dermatitis, other inflammatory skin conditions, including psoriasis, rosacea, Sjogren syndrome, acne, herpes type 1 & 2 and shingles, eosinophilic esophagitis, rheumatoid arthritis, non-alcoholic steatohepatitis, atherosclerosis, hypercholesteremia, diabetes type 1, Crohn's disease, inflammatory bowel disease, COVID-19, asthma, autoimmune disorders, age related macular dystrophy, diabetic retinopathy, conjunctivitis, uveitis, chronic sinusitis and Sjogren's syndrome. It is administered through topical route as cream. It is a 28-amino acid synthetic polypeptide. It acts by targeting leukocyte.

Amytrx Therapeutics overview

Amytrx Therapeutics, Inc., a clinical stage biopharmaceutical company advancing next-generation inflammation-targeting therapies. The company is headquartered in United States.

For a complete picture of AMTX-100’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.